Highlights:

• ~ 600M people live with diabetes, as per latest IDF Diabetes Atlas
• Advancing toward market launch
• Design optimization on track to reach design freeze and manufacturability
• Improved sensor sensitivity enhances data accuracy and performance
• Update on strategy, priorities and commercialization progress

Diabetes continues to be one of the most significant global health challenges, affecting more than 600 million people worldwide. Among them, over 110 million insulin-dependent patients require continuous glucose monitoring (CGM). CGM is the fastest-growing segment in diabetes technology, with an annual growth rate of 12.5% and a projected market size of USD 25 billion in Europe and the U.S. by 2030. Within this space, implantable CGMs are set to drive the next wave of innovation — and Lifecare is well-positioned to take part in this transformation.

“Our technology offers a novel approach to CGM by utilizing osmotic pressure as sensing principle to enable continuous, calibration-free glucose monitoring with extended wear times and improved comfort. Lifecare’s sensor is based on nanotechnology on a microchip and has a significant longevity potential, making our product very well suited as an implantable CGM solution. Lifecare’s patented technology is proven, based on in-vitro testing and several rounds of both clinical testing and pre-clinical testing”, says Lifecare’s CEO Joacim Holter.

Holter continous: “Manufacturability has been key focus in progress towards a product design freeze, including ongoing efforts for automation of production aligned with optimization of product and product tolerances. As planned and communicated we have validated stable product prototypes designed for manufacturing this quarter. We are now in the final engineering stages to lock in the design for manufacturing. The updated implant version will undergo further testing in spring 2025, forming the technical foundation for our main regulatory study. On this basis we aim to file for a pre-CE clinical study in Q2 2025, while we plan to start the pivotal study in late 2025 to support our CE-mark application”. Lifecare’s goal is to enter the human CGM market by 2027.

Lifecare’s short term strategic goals includes a capital efficient path towards commercialization with near term value inflection points. The Company aims to build a customer base of 75K patients within 2030, representing ~0.5% of the total addressable market, equating to an annual revenue of USD 200+ million.

In the meantime, Lifecare is leveraging the faster-moving veterinary market as an early commercialization opportunity. With no effective glucose monitoring solutions currently available for animals, this segment provides both a valuable business case and a real-world platform to build experience in manufacturing, logistics, and market feedback.

Lifecare’s scalable, partner-driven B2B model remains a core strength. The Company continues to invest in in-house capabilities, with a production facility opening in Mainz, Germany in Q3 2025. By combining internal control of design and production with a strategy to partner on sales, distribution, and customer support, the Company aims to ensure high quality, operational flexibility, and rapid scalability.

Lifecare’s Intellectual Property includes the patented technology, product software and hardware design, as well as production. To ensure state-of-the art user interface, Lifecare collaborates with OneTwo Analytics AB which provides AI-based digital tools for data interpretation and decision support. The digital software tools include software for both clinicians and the patients directly and is set up for integration and connectivity with insulin pumps (AIDs) and insulin pens. Lifecare has already integrated OneTwo Analytics software with its sensors designed to serve users in both the veterinary market and later the human market.

“With the scientific foundation established and our commercial strategy unfolding across both veterinary and human markets, we are entering a critical phase. The upcoming warrant exercise period in June 2025 will be instrumental in supporting our next steps. We are grateful for the continued support of our investors as we work toward CE approval, market entry, and long-term value creation”, says CEO Joacim Holter.

Q1 2025 results presentation and strategic update
CEO Joacim Holter and CFO Renete Kaarvik will present live at Hotel Continental, Stortingsgaten 24/26, Oslo today at 10:00 a.m. CEST.

To access the webcast Join the Teams-meeting here.
A recording of the webcast will be available on our website immediately after the event.

Following the presentation, Lifecare invites participants to 1:1 meetings with the CEO and CFO.
To register for physical attendance and to schedule a 1:1 meeting, please contact: kristin.samuelsen@dnb.no.